SI
BCRX icon

Standard Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Standard Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-73,500
Closed -$1.1M – 62
2015
Q2 		$1.1M Buy
+73,500
New +$836K 0.06% 89

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Standard Investments's BCRX Position: Q3 2015 in Review

Standard Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2015, closing a stake of 73,500 shares — an estimated $1.1M sold.

Standard Investments first reported a position in BCRX in Q2 2015 and held it in 1 quarter. The position peaked at $1.1M in Q2 2015. 124 funds tracked by Wall St. Rank hold BCRX as of Q3 2015.

  • Standard Investments reported no remaining BioCryst Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Standard Investments sold 73,500 BioCryst Pharmaceuticals shares in Q3 2015, an estimated $1.1M.
  • Standard Investments first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Standard Investments's BioCryst Pharmaceuticals position peaked at $1.1M in Q2 2015.
  • 124 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2015.

Based on Standard Investments's 13F filing for Q3 2015, filed 16 Nov 2015.